Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise in recent clinical trials. Nuclease-driven genome editing provides a method in which to precisely target genetic changes to further enhance T cell function in vivo. We describe the development of a highly efficient method to genome edit both primary human CD8 and CD4 T cells by homology-directed repair at a pre-defined site of the genome. Two different homology donor templates were evaluated, representing both minor gene editing events (restriction site insertion) to mimic gene correction, or the more significant insertion of a larger gene cassette. By combining zinc finger nuclease mRNA delivery with AAV6 delivery of a homologous donor we could gene correct 41% of CCR5 or 55% of PPP1R12C (AAVS1) alleles in CD8(+) T cells and gene targeting of a GFP transgene cassette in >40% of CD8(+) and CD4(+) T cells at both the CCR5 and AAVS1 safe harbor locus, potentially providing a robust genome editing tool for T cell-based immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Additional work has demonstrated that Adeno Associated Virus Serotype 6 (AAV6) functions as a highly efficient DNA template donor for homologous recombination (HR) in both hematopoietic stem cells and T cells15,16.”
From Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease (2018) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 2×
“Merged reads were filtered using the following criteria: the 5 and 3 ends (23 bp) must match the expected amplicon exactly, the read must not map to a different lo-cus in the target genome as determined by Bowtie2 (24) with default settings, and deletions must be 70% of the amplicon size or 70 bp long.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820 · cited 1×
“…nucleases (TALENs), and the RNA-guided clustered regularly interspaced short palindromic repeat (CRISPR) / Cas endonucleases, are a powerful class of enzymes that promote genome editing through the creation of a site-specific DNA double-strand break (DSB) at a pre-defined site in the genome (8).”
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506 · cited 1×
“Nucleic Acids Research, 2016, Vol. 44, No. 3 e30 CD8 + cytotoxic T lymphocytes (CTLs) have been proven to exhibit potent anti-tumor activity in preclinical and clinical studies (1–2 , 26– 28 ).”
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388 · cited 2×
“Furthermore, Engineered CD19-specific CD4 + T cell responses comprised at least part of the anti-tumor effects against B-cell malignance in a few of the recent successful clinical trials (26-28).”
Cited by
Items 101–130 of 130
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
“…generation of AAV6 vectors has been shown to be efficient in transduc ing primary human hematopoietic stem cells (128–131), primary human T cells (132), primary human mesenchymal stromal cells (133), primary human natural killer cells (134), primary human induced pluripotent stem cells (135),…”
Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway
Adabi, E., Charitidis, F. T., Thalheimer, F. B., Guaza-Lasheras, M., Clarke, C., & Buchholz, C. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101970 · Cited by 6
Dong, B., Xue, R., Li, J., Ling, S., Xing, W., Liu, Z., Yuan, X., Pan, J., Du, R., Shen, X., et al. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00186-y · Cited by 5
“And third, directly correcting abnormal gene structures through gene editing [65–70].”
BackgroundSynthetic mRNA for ex vivo therapeutic applications
Nakanishi, H., & Itaka, K. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100447 · Cited by 4
Guo, P., Yu, C., Wang, Q., Zhang, R., Meng, X., & Feng, Y. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.004 · Cited by 6
Editing of Endogenous Genes in Cellular Immunotherapies
Roth, T. L. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00587-0 · Cited by 3
Emerging CRISPR/Cas9 applications for T-cell gene editing
Preece, R., & Georgiadis, C. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180144 · Cited by 3
“Integration deficient lentiviral (IDLV) or adenoassociated viral (AAV) vectors used to transport large templates or entire genes into edited cells were met with modest efficiency with HDR ranging between 40%-60% [7, 27, 28].”
BackgroundGenome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
de Lima, S. C. G., Fantacini, D. M. C., Furtado, I. P., Rossetti, R., Silveira, R. M., Covas, D. T., & de Souza, L. E. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-33325-5_6 · Cited by 2
Stone, D., Meumann, N., Kuhlmann, A.-S., Peterson, C. W., Xie, H. J., Roychoudhury, P., Loprieno, M. A., Vu, X., Strongin, D. E., Kenkel, E. J., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000009 · Cited by 2
Boucher, J. D., Stranford, D. M., Edelstein, H. I., Tullman‐Ercek, D., Kamat, N. P., & Leonard, J. N. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70258 · Cited by 1
“We used AAV6 as it infects both primary T cells (Wang et al. 2015 ) and Jurkats (Ellis et al. 2013 ).”
Dong, R., Zhang, Y., Yuan, G., Yue, X., Ding, Y., Zeng, X., & Xiao, H. (2026) · Cancer Medicine · doi:10.1002/cam4.71918 · Cited by 1
“Compared to other capsid serotypes, AAV6 was reported to efficiently transduce αβ T cells [10].”
Gene Delivery Technologies for Efficient Genome Editing: Applications in Gene Therapy
Martín, F., Sánchez-Hernández, S., Gutiérrez-Guerrero, A., & Benabdellah, K. (2016) · InTech eBooks · doi:10.5772/62776 · Cited by 1
“Wang and colleagues [22], combined electroporation of ZFN mRNA (see below) with donor delivery by AAV serotype 6, achieving efficient GE in HSPCs (up to 50% of CCR5 specific insertion) and T cells.”
BackgroundBiomolecular Therapeutics for HIV
Li, S., & Burnett, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00018-5 · Cited by 1
Plasmid‐Based Donor Templates for Nonviral CRISPR/Cas9‐Mediated Gene Knock‐In in Human T Cells
Senger, K., Akhmetzyanova, I., Haley, B., Rutz, S., & Oh, S. A. (2022) · Current Protocols · doi:10.1002/cpz1.538 · Cited by 1
Therapeutic targeting non-coding RNAs
Ray, R. M., Lazăr, A. D., Balahura, L.-R., Dobranici, A., Costache, M., & Dinescu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90406-3.00006-3 · Cited by 2
Li, K., Zhang, Y., Wang, B., Mu, Y., Zhou, R., Dai, Y., Lai, L., Ruan, J., Liu, Z., Wu, T., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-819099-9.00002-9 · Cited by 1
HIV Receives a “One Two Knockout Punch”
Cruz, C. C., & Bollard, C. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.001
“For example, it was shown that such a mechanism may be utilized to specifically select a region where a transgene can be expressed (limiting insertional mutagenesis events) or, more intriguingly, to simultaneously disrupt a region expressing an unwanted gene and replace it with a foreign (or favorable) genetic constru…”
BackgroundGene-Editing Technologies and Applications for Molecular Imaging
Luker, G. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00061-2
Genome Editing Applications in Cancer T Cell Therapy
Nyberg, W. A., & Eyquem, J. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch16
ARCOBALENO cell therapy to treat pediatric cancer patients
Presti, V. L. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1187
Improved Long-term In Vivo Lentiviral Gene Therapy for Chronic Granulomatous DiseasePreprint
Yuan, H.-K., Yang, R., Gong, J., Wu, X., Liu, H., Liu, Y., & Chang, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2515847/v1
Moço, P. D. (2023) · eScholarship@McGill (McGill) · doi:10.82308/50772
An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells
Leng, M., Gan, C., Zheng, Z., He, S. N., Liu, Y., Zhou, L., Cheng, R., Zhou, J., Xiao, L., Ye, J., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261424779
Xie, S., Yang, Q., Jansen, L. V., Yao, B., Yang, G., Qu, K., Vader, P., Blok, C. S., de Jager, S. C. A., Boink, G. J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.727849
Jereb, S., D’Alessandro, L. R., Morshed, N., Chen, M., Sartore, R., Han, Z., McKinney, J. E., Brauer, P. P., Harvey, J. W., Demers, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.739854
“We evaluated its efficiency to transduce cultured primary human T cells, a cell type most efficiently targeted by AAV6 (Eyquem et al., 2017; Wang et al., 2016).”
From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy
Aldahshan, H., Al-Hubaysh, A., Alrabiah, D. K., Alturki, M., Alkharji, R. R., Lin, S., Aldughaim, M. S., & Albugami, R. R. (2026) · Biomedicines · doi:10.3390/biomedicines14091925
“Typically 20–50% with rAAV6; variable with non-viral donors [8,29,39].”
Jahnz, H., Hamann, M. V., Kim, H. O., Sun, Y., Salazar-Quiroz, N. A., Zhu, L., Leddy, S. M., Swaiba, U. E., Schneider, C., Foth, D., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261487919
From delivery to integration: CRISPR ‐mediated large insert gene editing in primary human T cells
Buttle, B., Verdon, D. J., & Sheppard, H. M. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70124
“41,51,93 T cells are also more tolerant to rAAV template length compared to naked DNA templates (Tables 1 – 3).”
Metadata
- Authors
- Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C.
- Affiliations
- Sangamo BioSciences (United States) (US)
- Corresponding author
- Wang, Jianbin
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-02
- Volume
- 44
- Issue
- 3
- Pages
- e30-e30
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC4756813
- OpenAlex
- W1909557371
- Semantic Scholar
- 9f6bb7afb7fabc85e007197bcf8398372df2e5ee
- Cited by
- 128
- References
- 54
- Citations by year
- 2026: 11 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 13 · 2021: 14 · 2020: 11 · 2019: 18 · 2018: 16 · 2017: 13 · 2016: 9
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nucleic Acids Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- genome editing, human T cells, zinc finger nucleases, AAV6 vector, homology-directed repair, CCR5, AAVS1 safe harbor, CD8+ T cells, CD4+ T cells, gene correction, adoptive T cell therapy, T cell engineering
- MeSH terms
- Dependovirus, Endonucleases, Genetic Vectors, Humans, RNA, Messenger, Transfection, CD4-Positive T-Lymphocytes, Genome, Human, Zinc Fingers, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.